Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Terapeutiske vacciner er et nyt behandlingsprincip ved kastrationsresistent prostatacancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{8a3d463a334e45d396e51a42d9e14477,
title = "Terapeutiske vacciner er et nyt behandlingsprincip ved kastrationsresistent prostatacancer",
abstract = "Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.",
author = "Djurhuus, {Sissal Sigmundsd{\'o}ttir} and Klaus Brasso and Berg, {Kasper Drimer} and Peter Iversen and R{\o}der, {Martin Andreas}",
year = "2015",
month = "5",
day = "11",
language = "Dansk",
volume = "177",
pages = "V11140628",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "20",

}

RIS

TY - JOUR

T1 - Terapeutiske vacciner er et nyt behandlingsprincip ved kastrationsresistent prostatacancer

AU - Djurhuus, Sissal Sigmundsdóttir

AU - Brasso, Klaus

AU - Berg, Kasper Drimer

AU - Iversen, Peter

AU - Røder, Martin Andreas

PY - 2015/5/11

Y1 - 2015/5/11

N2 - Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

AB - Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

M3 - Tidsskriftartikel

VL - 177

SP - V11140628

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 20

ER -

ID: 45343797